As of 2024-12-12, the Intrinsic Value of Royalty Pharma PLC (RPRX) is
38.45 USD. This RPRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 25.20 USD, the upside of Royalty Pharma PLC is
52.60%.
The range of the Intrinsic Value is 16.63 - 304.28 USD
38.45 USD
Intrinsic Value
RPRX Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
16.63 - 304.28 |
38.45 |
52.6% |
| DCF (Growth 10y) |
19.69 - 311.88 |
42.01 |
66.7% |
| DCF (EBITDA 5y) |
49.68 - 67.46 |
55.34 |
119.6% |
| DCF (EBITDA 10y) |
48.15 - 73.46 |
57.12 |
126.6% |
| Fair Value |
48.59 - 48.59 |
48.59 |
92.81% |
| P/E |
53.88 - 60.79 |
59.13 |
134.7% |
| EV/EBITDA |
18.80 - 170.77 |
65.18 |
158.7% |
| EPV |
(23.83) - (30.80) |
(27.32) |
-208.4% |
| DDM - Stable |
21.96 - 143.84 |
82.90 |
229.0% |
| DDM - Multi |
28.72 - 142.36 |
47.38 |
88.0% |
RPRX Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
14,847.34 |
| Beta |
0.03 |
| Outstanding shares (mil) |
589.18 |
| Enterprise Value (mil) |
21,504.67 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.21% |
| Cost of Debt |
5.50% |
| WACC |
6.30% |